Correction: Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Phase II evaluation of zanubrutinib plus R-CHOP for untreated diffuse large B-cell lymphoma with a specific gene alteration

  • By

  • Qunling Zhang

  • Shiyu Jiang

  • Ran Wei

  • Wenhao Zhang

  • Longlong Bao

  • Yizhen Liu

  • Jia Jin

  • Fangfang Lv

  • Chuanxu Liu

  • Xiaojian Liu

  • Hui Sun

  • Jiachen Wang

  • Rong Tao

  • Xiaoyan Zhou

  • Junning Cao

  • November 5, 2026

Share

Objective:

Report a correction to the article.

Approach:
  • Correction: The updated version of Fig. 2 was not included in the article during correction.
Key Findings:
  • The original article has undergone correction.
  • The correction was published online on 1 July 2026.
Interpretation:

The notice concerns the omission of the updated Fig. 2; it provides no further study findings.

Sources:

Original Source(s)

Correction: Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study

  • by Qunling Zhang, Shiyu Jiang, Ran Wei, Wenhao Zhang, Longlong Bao, Yizhen Liu, Jia Jin, Fangfang Lv, Chuanxu Liu, Xiaojian Liu, Hui Sun, Jiachen Wang, Rong Tao, Xiaoyan Zhou, Junning Cao

  • November 5, 2026

Related Content

From Evidence to Practice in Low-Risk Thyroid Cancer

The first attempts to transplant bone marrow—tribute to Jan Raszek-Rosenbusch and Franciszek Groër.

Error in Number of Cancers

  • October 27, 2026